Safe Accelerated Venetoclax Escalation: a phase 1b study of obinutuzumab plus venetoclax with daily ramp-up in CLL. [PDF]
Blood AdvCrombie JL +14 more
europepmc +1 more source
Obinutuzumab as a Rescue and Maintenance Strategy in Children with Difficult-to-Treat Nephrotic Syndrome After Rituximab-Based Treatment Failure or Intolerance: A Preliminary Single-Center Real-World Retrospective Study. [PDF]
Drug Des Devel TherSun H +6 more
europepmc +1 more source
Correction: Obinutuzumab as salvage anti-CD20 therapy in poly-refractory difficult-to-treat seropositive rheumatoid arthritis. [PDF]
Rheumatol Adv Practeuropepmc +1 more source
Obinutuzumab as salvage anti-CD20 therapy in poly-refractory difficult-to-treat seropositive rheumatoid arthritis. [PDF]
Rheumatol Adv PractMonjo-Henry I +7 more
europepmc +1 more source
Adverse event reporting patterns of rituximab and obinutuzumab in B-cell non-Hodgkin lymphoma: a FAERS pharmacovigilance study. [PDF]
Front ImmunolMa W, Fu H, Zhou Y, Wu Y.
europepmc +1 more source
Precision-guided therapy in dialysis-dependent classic hairy cell leukemia: a case report. [PDF]
Front OncolVeeraballi S, Chandra MB, Vick EJ.
europepmc +1 more source
Efficacy and safety of obinutuzumab in refractory membranous nephropathy: a single-arm meta-analysis. [PDF]
Front ImmunolCong P, Wang J, Du X.
europepmc +1 more source
Pulmonary Involvement in Chronic Lymphocytic Leukemia: A Structured Diagnostic Approach to Diffuse Infiltrates-A Case Report. [PDF]
EJHaemAguado B +4 more
europepmc +1 more source
Evidence for the use of anti-CD20 therapeutic antibodies in immune thrombotic thrombocytopenic purpura management: a review. [PDF]
Front PharmacolHalkidis K, Meng C, Snyder J.
europepmc +1 more source
Durability Benchmarking of Contemporary Second-Line and Later Therapies for Relapsed or Refractory Follicular Lymphoma Using Reconstructed Individual Patient Data From Published Kaplan-Meier Curves. [PDF]
CureusBurke OJ +3 more
europepmc +1 more source